Phase 2 Trial Planned for FHL-301 in Treating Early Stage Parkinson’s

Phase 2 Trial Planned for FHL-301 in Treating Early Stage Parkinson’s

300240

Phase 2 Trial Planned for FHL-301 in Treating Early Stage Parkinson’s

Forest Hills Lab announced that it has U.S. Food and Drug Administration (FDA) permission to open a Phase 2 trial into the tolerability and potential efficacy of FHL-301 in people in the early stages of Parkinson’s disease. The double-blinded trial will randomly assign patients to the investigative treatment or to a placebo for 52 weeks (one year). “We are very excited and pleased with the FDA approval to proceed with this Phase 2 clinical trial for this neurodegenerative disease,”…

You must be logged in to read/download the full post.